Sticking with hormone therapy for five years after breast cancer surgery cut deaths but raised the 10-year risk of high blood pressure, unhealthy cholesterol, and diabetes, a study of 8,365 postmenopausal women published in JNCI Cancer Spectrum found — with the risks differing sharply between aromatase inhibitors and tamoxifen.
The findings matter because roughly 80% of breast cancers are hormone receptor–positive, and adjuvant endocrine therapy taken daily for at least five years remains the cornerstone of treatment for these patients, as the study team notes in the paper. With more than 4.3 million breast cancer survivors in the United States, the long-term cardiometabolic consequences of these drugs have become a survivorship question in their own right.
Trade-off raises cardiometabolic risks differently by drug
- The trade-off was a modestly higher chance of developing high blood pressure, abnormal cholesterol, or diabetes over ten years, and the profile differed by drug.
- Neither drug is “worse” overall: aromatase inhibitors raised cholesterol risk more, tamoxifen raised diabetes risk only in women with obesity, and both drugs showed identical hypertension rates.
The trade-off, in numbers
Compared with nonadherence, five years of consistent therapy was associated with a higher 10-year cumulative incidence of hypertension (an absolute difference of 8.81%; 95% CI, 4.25–13.4), dyslipidemia (5.16%; 95% CI, 0.31–10.0), and diabetes (2.58%; 95% CI, 0.02–5.14) — but a 10.7% lower risk of all-cause death (95% CI, 7.74–13.7) and a 5.37% lower risk of breast cancer–specific death (95% CI, 3.36–7.38).
Tamoxifen adherence was linked only to hypertension (9.38%; 95% CI, 2.71%–16.10%); its dyslipidemia and diabetes estimates were not statistically significant.
“Despite these risks, [adjuvant endocrine therapy] was associated with improved survival.”
In a direct comparison of adherent patients, aromatase inhibitor use carried a 9.86% higher absolute 10-year incidence of dyslipidemia than tamoxifen (95% CI, 5.09%–14.60%) — 32.5% versus 22.7%. Hypertension incidence was identical at 29.2% in both groups, and the diabetes difference (2.93%; 95% CI, –0.36% to 6.21%) was not statistically significant.
| 10-year outcome (adherent patients) | Aromatase inhibitor | Tamoxifen |
|---|---|---|
| Hypertension | 29.2% | 29.2% |
| Dyslipidemia | 32.5% (95% CI, 29.8–35.3) | 22.7% (95% CI, 18.8–26.6) |
| Diabetes difference (AI vs tamoxifen) | 2.93% (95% CI, –0.36 to 6.21) — not significant | |
How the study measured adherence
The cohort came from the Pathways Heart Study, a prospective cohort within Kaiser Permanente Northern California, and included postmenopausal women aged 50 or older at diagnosis with stage I to III hormone receptor–positive breast cancer who started endocrine therapy between 2005 and 2013. The median age at diagnosis was 64; 90.9% had stage I or II disease, and 32.5% received chemotherapy.
The team estimated 10-year cumulative incidence under six adherence duration strategies using sequentially doubly robust estimation — a statistical method that, in plain terms, combines regression modeling with weighting to reduce bias — adjusting for demographic, clinical, lifestyle, and tumor characteristics, and treating death from any cause as a competing risk.
Most patients (67%) took only an aromatase inhibitor, 10% took only tamoxifen, and 10% switched between the two. Overall, 42.7% were continuously adherent for at least five years; 12.8% were nonadherent. Findings held in sensitivity analyses using adherence thresholds of 60% and 70% and a stricter age cutoff of 55, per the study abstract.
Obesity changed the tamoxifen picture
Body mass index modified some associations. Among women with a BMI of 30 or higher, five-year tamoxifen adherence was associated with an 11.1% higher 10-year diabetes risk (95% CI, 3.32%–18.90%). Among women without obesity, it was associated with a 4.42% lower risk (95% CI, –6.71% to –2.12%).
That distinction matters for the growing share of survivors who enter treatment with metabolic risk factors.
Why earlier studies missed this
Cumulative incidence curves showed the largest differences in risk emerging after five years of therapy — which, the authors noted, may explain why earlier studies with shorter follow-up did not detect some of these associations.
There was a puzzle in the mortality data: adherence was associated with more cardiometabolic risk factors but lower cardiovascular mortality.
What the study cannot tell us
The limitations, as listed in the paper, are substantial. Adherence was based on dispensing rather than actual medication-taking, and outcomes were defined by clinical algorithms rather than physiological biomarkers. There was no data on why patients discontinued therapy.
Obesity and rising levels signal need for monitoring talks
Women with obesity considering or taking tamoxifen, and anyone on an aromatase inhibitor with rising blood pressure or lipids, have the clearest signal warranting a conversation with their care team about cardiometabolic monitoring, consistent with the monitoring windows the investigators themselves identified.
The study appeared in JNCI Cancer Spectrum, a fully open access journal established in 2017 and published bimonthly by Oxford University Press under editor Ronald Chen.
It is the youngest branch of a publishing family that traces back to August 1940, when the Journal of the National Cancer Institute was founded by the U.S. National Cancer Institute — a journal the NCI ran as its official outlet until the two agreed to grow apart in 1996, leaving JNCI independent of its founding institute over the following five years.
Where the research goes next
The authors called for mediation analyses to clarify whether cardiometabolic risk factors influence cardiovascular events among breast cancer survivors — the open question the study leaves behind.
References
- Ledesma JR, Nugent J, Cheng R, et al. Endocrine therapy adherence and 10-year cardiometabolic risk in hormone receptor-positive breast cancer. JNCI Cancer Spectrum. 2026;10(6):pkag095. doi:10.1093/jncics/pkag095 — https://doi.org/10.1093/jncics/pkag095
- Europe PMC abstract record, PMID 42786642
Worth a look
- Vietnamese Surgeons Remove Malignant Brain Tumor From 63-Year-Old Woman Preserving Function
- Scientists and Foundations Patch U.S. Research After Federal Cuts
- Jessie J Returns to Instagram After Breast Reconstruction Surgery (newsdirectory3.com)
- Tsama, Survivors Take Uganda to UN Committee (archyworldys.com)